Investors sold shares of Bristol-Myers Squibb Company (NYSE:BMY) on strength during trading hours on Tuesday. $38.37 million flowed into the stock on the tick-up and $75.14 million flowed out of the stock on the tick-down, for a money net flow of $36.77 million out of the stock. Of all stocks tracked, Bristol-Myers Squibb had the 0th highest net out-flow for the day. Bristol-Myers Squibb traded up $0.44 for the day and closed at $61.24
Several equities analysts have weighed in on BMY shares. BMO Capital Markets restated an “underperform” rating and set a $47.00 target price (down from $51.00) on shares of Bristol-Myers Squibb in a report on Wednesday, July 26th. Vetr upgraded shares of Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating and set a $64.33 target price for the company in a report on Wednesday, July 26th. Piper Jaffray Companies set a $60.00 target price on shares of Bristol-Myers Squibb and gave the company a “hold” rating in a report on Thursday, July 27th. Leerink Swann dropped their target price on shares of Bristol-Myers Squibb from $66.00 to $61.00 and set an “outperform” rating for the company in a report on Friday, July 28th. Finally, BidaskClub downgraded shares of Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a report on Monday, July 31st. One research analyst has rated the stock with a sell rating, ten have given a hold rating and eleven have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $64.93.
The company has a debt-to-equity ratio of 0.47, a current ratio of 1.59 and a quick ratio of 1.46. The company has a market cap of $100,231.52, a PE ratio of 20.69, a PEG ratio of 2.41 and a beta of 1.18.
Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.77 by ($0.02). Bristol-Myers Squibb had a return on equity of 32.41% and a net margin of 20.56%. The company had revenue of $5.25 billion during the quarter, compared to analyst estimates of $5.20 billion. During the same period in the prior year, the business posted $0.77 earnings per share. Bristol-Myers Squibb’s revenue was up 6.7% on a year-over-year basis. research analysts forecast that Bristol-Myers Squibb Company will post 2.99 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which was paid on Wednesday, November 1st. Investors of record on Friday, October 6th were given a $0.39 dividend. The ex-dividend date was Thursday, October 5th. This represents a $1.56 annualized dividend and a dividend yield of 2.55%. Bristol-Myers Squibb’s dividend payout ratio is presently 61.42%.
In related news, SVP Joseph C. Caldarella sold 9,340 shares of the firm’s stock in a transaction that occurred on Wednesday, September 6th. The shares were sold at an average price of $60.00, for a total value of $560,400.00. Following the sale, the senior vice president now directly owns 46,297 shares of the company’s stock, valued at $2,777,820. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.23% of the stock is currently owned by company insiders.
A number of hedge funds have recently made changes to their positions in the business. Blue Chip Partners Inc. lifted its position in Bristol-Myers Squibb by 0.7% during the second quarter. Blue Chip Partners Inc. now owns 2,156 shares of the biopharmaceutical company’s stock valued at $120,000 after buying an additional 15 shares in the last quarter. Jackson Grant Investment Advisers Inc. lifted its position in Bristol-Myers Squibb by 0.4% during the second quarter. Jackson Grant Investment Advisers Inc. now owns 3,905 shares of the biopharmaceutical company’s stock valued at $218,000 after buying an additional 15 shares in the last quarter. Keel Point LLC lifted its position in Bristol-Myers Squibb by 0.3% during the first quarter. Keel Point LLC now owns 6,286 shares of the biopharmaceutical company’s stock valued at $342,000 after buying an additional 18 shares in the last quarter. Staley Capital Advisers Inc. lifted its position in Bristol-Myers Squibb by 0.3% during the first quarter. Staley Capital Advisers Inc. now owns 6,962 shares of the biopharmaceutical company’s stock valued at $379,000 after buying an additional 24 shares in the last quarter. Finally, Shayne & CO. LLC lifted its position in Bristol-Myers Squibb by 0.6% during the second quarter. Shayne & CO. LLC now owns 4,041 shares of the biopharmaceutical company’s stock valued at $225,000 after buying an additional 24 shares in the last quarter. 68.97% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: “Investors Sell Shares of Bristol-Myers Squibb Company (BMY) on Strength (BMY)” was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another site, it was stolen and reposted in violation of United States & international trademark and copyright legislation. The legal version of this piece of content can be read at https://www.dispatchtribunal.com/2017/11/23/investors-sell-shares-of-bristol-myers-squibb-company-bmy-on-strength-bmy-2.html.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.